leisure time -WSS

leisure time

author：entertainment 2025-08-22 20:55:19 - browse：61774

Duchenne muscular dystrophy Histopathology — Duchenne muscular dystrophy histopathology. Dr. Edwin P. Ewing, Jr./CDC

Japanese drugmaker Nippon Shinyaku said on Monday that its Duchenne muscular dystrophy drug, Viltepso, part of a controversial class of treatments for the rare disease, had failed to reach its primary endpoint in a placebo-controlled confirmatory trial.

Children who received the drug could stand up faster from the floor at the end of the study, but so could children who received a placebo. There was no statistically significant difference between the groups.

Although Nippon did not release detailed data, the failure is notable because Viltepso belongs to a contentious class of drugs called exon-skippers. Duchenne is caused by mutations in a muscle-supporting gene called dystrophin. These drugs are designed to increase the amount of dystrophin protein that patients with specific mutations produce. But the drugs only lead to slight increases in protein levels, and their clinical benefits have never been proven in a large, placebo-controlled study.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Readout Newsletter: Bayer study halts, Carmot to IPO, and more

leisure time

WSS

Morphosys mixed study results for blood cancer drug

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

PBM reforms clear House panel

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

Weight loss drug costs may need more research, senator suggests

Surge of respiratory disease in China has likely explanation

hotspot

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

New air purifier tech could be key to improving indoor air quality

Prior authorization will have to move faster under new Biden rule

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Test for long Covid? Researchers find new clue in blood samples

Hepatitis C has a cure — but many Americans still lack access to it

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

Wildfire smoke exposes gaps in outdoor worker protections

Ransomware attacks on hospitals: Study outlines patient impact

explore

Astellas still sees hope in its gene therapy after four deaths

Test for long Covid? Researchers find new clue in blood samples

Astellas still sees hope in its gene therapy after four deaths

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

AI generated plenty of interest at JPM but not a lot of trust

EU regulator recommends expanding Mounjaro approval to obesity

leisure time

leisure time

hotspot

leisure time